akn
Musclechemistry Member
<!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <wunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <woNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <wontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <wontVertAlignCellWithSp/> <wontBreakConstrainedForcedTables/> <wontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> <w:UseFELayout/> </w:Compatibility> <woNotOptimizeForBrowser/> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="--"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument> </xml><![endif]--> [FONT="]Description:[/FONT]
[FONT="]Methylandrostenediol (methandriol for short) is an anabolic[/FONT]
[FONT="]steroid derived from dihydrotestosterone. The drug itself is[/FONT]
[FONT="]manufactured in two very distinct forms. The first is[/FONT]
[FONT="]unesterified (straight) methylandrostenediol, which is used[/FONT]
[FONT="]when making an oral medication with this steroid (although[/FONT]
[FONT="]an injectable once existed in the U.S.). It is also found as[/FONT]
[FONT="]esterified methylandrostenediol dipropionate, which is[/FONT]
[FONT="]prepared as an injectable. The added propionate esters in the[/FONT]
[FONT="]injectable form extend the activity of the drug for several[/FONT]
[FONT="]days. Basically, methandriol drugs are altered c17-alkylated[/FONT]
[FONT="]forms of 5-androstenediol. Methandriol is classified as a[/FONT]
[FONT="]weak anabolic with weak androgenic properties. It also[/FONT]
[FONT="]seems to display some level of estrogenic activity, making[/FONT]
[FONT="]this steroid less ideal for dieting. The drug is generally[/FONT]
[FONT="]considered too mild, and is not widely popular among[/FONT]
[FONT="]bodybuilders and athletes. Sometimes, however, it is used in[/FONT]
[FONT="]place of other anabolic/androgenic agents in bulking stacks[/FONT]
[FONT="]when available.[/FONT]
[FONT="]History:[/FONT]
[FONT="]Methylandrostenediol was first described in 1935,533 making[/FONT]
[FONT="]this a very old agent as far as synthetic anabolic steroids are[/FONT]
[FONT="]concerned. Methylandrostendiol was developed into a[/FONT]
[FONT="]medicine by Organon, which sold it in the United States[/FONT]
[FONT="]under the Stenediol brand name in both oral[/FONT]
[FONT="](methylandrostenediol) and injectable (methylandrostendiol[/FONT]
[FONT="]dipropionate) forms. Many other generics and other brands[/FONT]
[FONT="]of methylandrostenediol soon followed, and the drug was a[/FONT]
[FONT="]popular anabolic agent in the United States during the[/FONT]
[FONT="]1950’s. Methylandrostenediol was essentially the first[/FONT]
[FONT="]steroid perceived to have a notable separation of anabolic[/FONT]
[FONT="](higher) and androgenic (lower) effect, a persistent goal of[/FONT]
[FONT="]pharmaceutical developers. Early product literature[/FONT]
[FONT="]described it as, “a steroid which has considerable of the[/FONT]
[FONT="]male hormone’s tissue-building action without to the same[/FONT]
[FONT="]extent causing virilization.”534 It was indicated for use as a,[/FONT]
[FONT="]“tissue-builder in cases of retarded growth or failure to gain[/FONT]
[FONT="]weight accompanied by protein wastage, negative nitrogen[/FONT]
[FONT="]balance, or failure to build body proteins.”[/FONT]
[FONT="]Early assessments of methylandrostenediol being primarily[/FONT]
[FONT="]anabolic in nature did not hold up well with later extensive[/FONT]
[FONT="]use in humans. It was eventually determined that in doses[/FONT]
[FONT="]sufficient to promote weight gain, its anabolic properties[/FONT]
[FONT="]were accompanied by significant androgenic activity.[/FONT]
[FONT="]Ultimately, this drug would be viewed as one of balanced[/FONT]
[FONT="]anabolic and androgenic action, not as a highly anabolic[/FONT]
[FONT="]agent as originally thought. Organon would go on to develop[/FONT]
[FONT="]more effective anabolic agents, such as their 19-nor series of[/FONT]
[FONT="]drugs including Durabolin, Deca-Durabolin, and Maxibolin,[/FONT]
[FONT="]and eventually discontinued the Stenediol products. The[/FONT]
[FONT="]other U.S. brand and generic forms of the drug would follow[/FONT]
[FONT="]as well, although methylandrostenediol would persist in the[/FONT]
[FONT="]U.S. scene for some time. Currently, no domestic source of[/FONT]
[FONT="]the drug exists, although it is still found in certain[/FONT]
[FONT="]international markets. It seems most prominent in Australia at[/FONT]
[FONT="]the present time, where it remains included in a number of[/FONT]
[FONT="]veterinary anabolic steroid products.[/FONT]
[FONT="]How Supplied:[/FONT]
[FONT="]Methylandrostendiol is available in select human and[/FONT]
[FONT="]veterinary drug markets. Composition and dosage may vary[/FONT]
[FONT="]by country and manufacturer.[/FONT]
[FONT="]Structural Characteristics:[/FONT]
[FONT="]Methylandrostendiol is a modified form of[/FONT]
[FONT="]dihydrotestosterone. It differs by: 1) the addition of a methyl[/FONT]
[FONT="]group at carbon 17-alpha to protect the hormone during oral[/FONT]
[FONT="]administration and 2) the introduction of a double bond[/FONT]
[FONT="]between carbons 5 and 6, which seems to increase the[/FONT]
[FONT="]anabolic strength of the steroid (partly by making it resistant[/FONT]
[FONT="]to metabolism by 3-hydroxysteroid dehydrogenase in skeletal[/FONT]
[FONT="]muscle tissue). Methylandrostenediol dipropionate contains[/FONT]
[FONT="]methylandrostenediol modified with the addition of 2[/FONT]
[FONT="]carboxylic acid esters (propionic acid) at the 3-beta and 17-[/FONT]
[FONT="]beta hydroxyl groups, which delay the release of free[/FONT]
[FONT="]methylandrostenediol from the site of injection (depot).[/FONT]
[FONT="]Side Effects (Estrogenic):[/FONT]
[FONT="]Methylandrostendiol is not directly aromatized by the body,[/FONT]
[FONT="]although one of its known metabolites is methyltestosterone,[/FONT]
[FONT="]which can aromatize. Methlyandrostenediol is also believed[/FONT]
[FONT="]to have some inherent estrogenic activity. It is, likewise,[/FONT]
[FONT="]considered a weakly to moderately estrogenic steroid.[/FONT]
[FONT="]Gynecomastia is possible during treatment, but generally[/FONT]
[FONT="]only when higher doses are used. Water and fat retention can[/FONT]
[FONT="]also become issues, again depending on dose. Sensitive[/FONT]
[FONT="]individuals may need to addition an anti-estrogen such as[/FONT]
[FONT="]Nolvadex® to minimize related side effects.[/FONT]
[FONT="]Side Effects (Androgenic):[/FONT]
[FONT="]Although often classified as an anabolic steroid,[/FONT]
[FONT="]methylandrostenediol is sufficiently androgenic. Androgenic[/FONT]
[FONT="]side effects are common with this substance. This may[/FONT]
[FONT="]include bouts of oily skin, acne, and body/facial hair growth.[/FONT]
[FONT="]Anabolic/androgenic steroids may also aggravate male[/FONT]
[FONT="]pattern hair loss. Women are warned of the potential[/FONT]
[FONT="]virilizing effects of anabolic/androgenic steroids. These may[/FONT]
[FONT="]include a deepening of the voice, menstrual irregularities,[/FONT]
[FONT="]changes in skin texture, facial hair growth, and clitoral[/FONT]
[FONT="]enlargement. Note that methylandrostenediol is not affected[/FONT]
[FONT="]by 5-alpha reductase, so the relative androgenicity of this[/FONT]
[FONT="]steroid is not affected by the concurrent use of finasteride or[/FONT]
[FONT="]dutasteride.[/FONT]
[FONT="]Side Effects (Hepatotoxicity):[/FONT]
[FONT="]Methylandrostenediol is a c17-alpha alkylated compound.[/FONT]
[FONT="]This alteration protects the drug from deactivation by the[/FONT]
[FONT="]liver, allowing a very high percentage of the drug entry into[/FONT]
[FONT="]the bloodstream following oral administration. C17-alpha[/FONT]
[FONT="]alkylated anabolic/androgenic steroids can be hepatotoxic.[/FONT]
[FONT="]Prolonged or high exposure may result in liver damage. In[/FONT]
[FONT="]rare instances life-threatening dysfunction may develop. It is[/FONT]
[FONT="]advisable to visit a physician periodically during each cycle[/FONT]
[FONT="]to monitor liver function and overall health. Intake of c17-[/FONT]
[FONT="]alpha alkylated steroids is commonly limited to 6-8 weeks,[/FONT]
[FONT="]in an effort to avoid escalating liver strain. Injectable forms[/FONT]
[FONT="]of the drug may present slightly less strain on the liver by[/FONT]
[FONT="]avoiding the first pass metabolism of oral dosing, although[/FONT]
[FONT="]may still present substantial hepatotoxicity.[/FONT]
[FONT="]The use of a liver detoxification supplement such as Liver[/FONT]
[FONT="]Stabil, Liv-52, or Essentiale Forte is advised while taking[/FONT]
[FONT="]any hepatotoxic anabolic/androgenic steroids.[/FONT]
[FONT="]Side Effects (Cardiovascular):[/FONT]
[FONT="]Anabolic/androgenic steroids can have deleterious effects on[/FONT]
[FONT="]serum cholesterol. This includes a tendency to reduce HDL[/FONT]
[FONT="](good) cholesterol values and increase LDL (bad)[/FONT]
[FONT="]cholesterol values, which may shift the HDL to LDL balance[/FONT]
[FONT="]in a direction that favors greater risk of arteriosclerosis. The[/FONT]
[FONT="]relative impact of an anabolic/androgenic steroid on serum[/FONT]
[FONT="]lipids is dependant on the dose, route of administration (oral[/FONT]
[FONT="]vs. injectable), type of steroid (aromatizable or nonaromatizable),[/FONT]
[FONT="]and level of resistance to hepatic metabolism.[/FONT]
[FONT="]Methylandrostenediol has a strong effect on the hepatic[/FONT]
[FONT="]management of cholesterol due to its structural resistance to[/FONT]
[FONT="]liver breakdown and (with the oral) route of administration.[/FONT]
[FONT="]Anabolic/androgenic steroids may also adversely affect[/FONT]
[FONT="]blood pressure and triglycerides, reduce endothelial[/FONT]
[FONT="]relaxation, and support left ventricular hypertrophy, all[/FONT]
[FONT="]potentially increasing the risk of cardiovascular disease and[/FONT]
[FONT="]myocardial infarction.[/FONT]
[FONT="]To help reduce cardiovascular strain it is advised to[/FONT]
[FONT="]maintain an active cardiovascular exercise program and[/FONT]
[FONT="]minimize the intake of saturated fats, cholesterol, and simple[/FONT]
[FONT="]carbohydrates at all times during active AAS administration.[/FONT]
[FONT="]Supplementing with fish oils (4 grams per day) and a natural[/FONT]
[FONT="]cholesterol/antioxidant formula such as Lipid Stabil or a[/FONT]
[FONT="]product with comparable ingredients is also recommended.[/FONT]
[FONT="]Side Effects (Testosterone Suppression):[/FONT]
[FONT="]All anabolic/androgenic steroids when taken in doses[/FONT]
[FONT="]sufficient to promote muscle gain are expected to suppress[/FONT]
[FONT="]endogenous testosterone production. Without the intervention[/FONT]
[FONT="]of testosterone-stimulating substances, testosterone levels[/FONT]
[FONT="]should return to normal within 1-4 months of drug secession.[/FONT]
[FONT="]Note that prolonged hypogonadotrophic hypogonadism can[/FONT]
[FONT="]develop secondary to steroid abuse, necessitating medical[/FONT]
[FONT="]intervention[/FONT]
[FONT="]Administration (General):[/FONT]
[FONT="]Studies have shown that taking an oral anabolic steroid with[/FONT]
[FONT="]food may decrease its bioavailability. This is caused by the[/FONT]
[FONT="]fat-soluble nature of steroid hormones, which can allow[/FONT]
[FONT="]some of the drug to dissolve with undigested dietary fat,[/FONT]
[FONT="]reducing its absorption from the gastrointestinal tract. For[/FONT]
[FONT="]maximum utilization, oral forms of this steroid should be[/FONT]
[FONT="]taken on an empty stomach.[/FONT]
[FONT="]Administration (Men):[/FONT]
[FONT="]Early prescribing guidelines for Stenediol recommend a[/FONT]
[FONT="]dosage of 25 mg given 2 to 5 times per week by oral, buccal,[/FONT]
[FONT="]or intramuscular route. For physique- or performanceenhancing[/FONT]
[FONT="]purposes, a typical dosage is in the range of 25-50[/FONT]
[FONT="]mg daily for the oral form, and 200-400 mg per week with[/FONT]
[FONT="]the injectable. In order to keep blood levels more even with[/FONT]
[FONT="]the injectable, it is generally administered once every three[/FONT]
[FONT="]to four days. Cycles generally last for no more than 6 to 8[/FONT]
[FONT="]weeks, in an effort to minimize hepatotoxicity and strain on[/FONT]
[FONT="]the liver and cholesterol values. This level of use is[/FONT]
[FONT="]sufficient for moderate gains in muscle size and strength,[/FONT]
[FONT="]which may be accompanied by a low level of water[/FONT]
[FONT="]retention[/FONT]
[FONT="]While it may be possible to use methylandrostenediol alone[/FONT]
[FONT="]for muscle-building purposes, it is most often combined with[/FONT]
[FONT="]other anabolics for a stronger effect. Combined with Deca-[/FONT]
[FONT="]Durabolin® or Equipoise®, for example, measurable gains[/FONT]
[FONT="]of hard muscle mass, without an extreme level of water[/FONT]
[FONT="]retention, may be noticed. This is the general composition of[/FONT]
[FONT="]most Australian vet blends that include[/FONT]
[FONT="]methylandrostenediol. When looking for a more pronounced[/FONT]
[FONT="]gain in mass, a stronger androgen such as testosterone may be[/FONT]
[FONT="]added. The resulting growth can be quite exceptional, but the[/FONT]
[FONT="]user will also have to deal with a much stronger set of[/FONT]
[FONT="]estrogenic side effects. The drug sometimes also combines[/FONT]
[FONT="]well with non-aromatizing anabolics such as Winstrol®,[/FONT]
[FONT="]Primobolan®, or oxandrolone. The result here should be a[/FONT]
[FONT="]more pronounced effect on muscle hardness, with a moderate[/FONT]
[FONT="]gain of solid lean tissue.[/FONT]
[FONT="]Administration (Women):[/FONT]
[FONT="]Early prescribing guidelines for Stenediol recommend a[/FONT]
[FONT="]dosage of 25 mg given 2 to 5 times per week by oral, buccal,[/FONT]
[FONT="]or intramuscular route. Methylandrostenediol is generally not[/FONT]
[FONT="]recommended for women for physique- or performanceenhancing[/FONT]
[FONT="]purposes due to its androgenic nature and tendency[/FONT]
[FONT="]to produce virilizing side effects.[/FONT]
[FONT="]Availability:[/FONT]
[FONT="]Pharmaceutical preparations containing[/FONT]
[FONT="]methylandrostenediol remain scarce. In reviewing some of[/FONT]
[FONT="]the remaining products and changes in the global[/FONT]
[FONT="]pharmaceutical market, we have made the following[/FONT]
[FONT="]observations.[/FONT]
[FONT="]The only place where this steroid is still produced in an[/FONT]
[FONT="]volume is Australia, where a number of veterinary[/FONT]
[FONT="]preparations still include methandriol in their blends. These[/FONT]
[FONT="]products are rarely traded in international commerce due to[/FONT]
[FONT="]tight controls on anabolic steroids in that country[/FONT][FONT="][/FONT]
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->
[FONT="]Methylandrostenediol (methandriol for short) is an anabolic[/FONT]
[FONT="]steroid derived from dihydrotestosterone. The drug itself is[/FONT]
[FONT="]manufactured in two very distinct forms. The first is[/FONT]
[FONT="]unesterified (straight) methylandrostenediol, which is used[/FONT]
[FONT="]when making an oral medication with this steroid (although[/FONT]
[FONT="]an injectable once existed in the U.S.). It is also found as[/FONT]
[FONT="]esterified methylandrostenediol dipropionate, which is[/FONT]
[FONT="]prepared as an injectable. The added propionate esters in the[/FONT]
[FONT="]injectable form extend the activity of the drug for several[/FONT]
[FONT="]days. Basically, methandriol drugs are altered c17-alkylated[/FONT]
[FONT="]forms of 5-androstenediol. Methandriol is classified as a[/FONT]
[FONT="]weak anabolic with weak androgenic properties. It also[/FONT]
[FONT="]seems to display some level of estrogenic activity, making[/FONT]
[FONT="]this steroid less ideal for dieting. The drug is generally[/FONT]
[FONT="]considered too mild, and is not widely popular among[/FONT]
[FONT="]bodybuilders and athletes. Sometimes, however, it is used in[/FONT]
[FONT="]place of other anabolic/androgenic agents in bulking stacks[/FONT]
[FONT="]when available.[/FONT]
[FONT="]History:[/FONT]
[FONT="]Methylandrostenediol was first described in 1935,533 making[/FONT]
[FONT="]this a very old agent as far as synthetic anabolic steroids are[/FONT]
[FONT="]concerned. Methylandrostendiol was developed into a[/FONT]
[FONT="]medicine by Organon, which sold it in the United States[/FONT]
[FONT="]under the Stenediol brand name in both oral[/FONT]
[FONT="](methylandrostenediol) and injectable (methylandrostendiol[/FONT]
[FONT="]dipropionate) forms. Many other generics and other brands[/FONT]
[FONT="]of methylandrostenediol soon followed, and the drug was a[/FONT]
[FONT="]popular anabolic agent in the United States during the[/FONT]
[FONT="]1950’s. Methylandrostenediol was essentially the first[/FONT]
[FONT="]steroid perceived to have a notable separation of anabolic[/FONT]
[FONT="](higher) and androgenic (lower) effect, a persistent goal of[/FONT]
[FONT="]pharmaceutical developers. Early product literature[/FONT]
[FONT="]described it as, “a steroid which has considerable of the[/FONT]
[FONT="]male hormone’s tissue-building action without to the same[/FONT]
[FONT="]extent causing virilization.”534 It was indicated for use as a,[/FONT]
[FONT="]“tissue-builder in cases of retarded growth or failure to gain[/FONT]
[FONT="]weight accompanied by protein wastage, negative nitrogen[/FONT]
[FONT="]balance, or failure to build body proteins.”[/FONT]
[FONT="]Early assessments of methylandrostenediol being primarily[/FONT]
[FONT="]anabolic in nature did not hold up well with later extensive[/FONT]
[FONT="]use in humans. It was eventually determined that in doses[/FONT]
[FONT="]sufficient to promote weight gain, its anabolic properties[/FONT]
[FONT="]were accompanied by significant androgenic activity.[/FONT]
[FONT="]Ultimately, this drug would be viewed as one of balanced[/FONT]
[FONT="]anabolic and androgenic action, not as a highly anabolic[/FONT]
[FONT="]agent as originally thought. Organon would go on to develop[/FONT]
[FONT="]more effective anabolic agents, such as their 19-nor series of[/FONT]
[FONT="]drugs including Durabolin, Deca-Durabolin, and Maxibolin,[/FONT]
[FONT="]and eventually discontinued the Stenediol products. The[/FONT]
[FONT="]other U.S. brand and generic forms of the drug would follow[/FONT]
[FONT="]as well, although methylandrostenediol would persist in the[/FONT]
[FONT="]U.S. scene for some time. Currently, no domestic source of[/FONT]
[FONT="]the drug exists, although it is still found in certain[/FONT]
[FONT="]international markets. It seems most prominent in Australia at[/FONT]
[FONT="]the present time, where it remains included in a number of[/FONT]
[FONT="]veterinary anabolic steroid products.[/FONT]
[FONT="]How Supplied:[/FONT]
[FONT="]Methylandrostendiol is available in select human and[/FONT]
[FONT="]veterinary drug markets. Composition and dosage may vary[/FONT]
[FONT="]by country and manufacturer.[/FONT]
[FONT="]Structural Characteristics:[/FONT]
[FONT="]Methylandrostendiol is a modified form of[/FONT]
[FONT="]dihydrotestosterone. It differs by: 1) the addition of a methyl[/FONT]
[FONT="]group at carbon 17-alpha to protect the hormone during oral[/FONT]
[FONT="]administration and 2) the introduction of a double bond[/FONT]
[FONT="]between carbons 5 and 6, which seems to increase the[/FONT]
[FONT="]anabolic strength of the steroid (partly by making it resistant[/FONT]
[FONT="]to metabolism by 3-hydroxysteroid dehydrogenase in skeletal[/FONT]
[FONT="]muscle tissue). Methylandrostenediol dipropionate contains[/FONT]
[FONT="]methylandrostenediol modified with the addition of 2[/FONT]
[FONT="]carboxylic acid esters (propionic acid) at the 3-beta and 17-[/FONT]
[FONT="]beta hydroxyl groups, which delay the release of free[/FONT]
[FONT="]methylandrostenediol from the site of injection (depot).[/FONT]
[FONT="]Side Effects (Estrogenic):[/FONT]
[FONT="]Methylandrostendiol is not directly aromatized by the body,[/FONT]
[FONT="]although one of its known metabolites is methyltestosterone,[/FONT]
[FONT="]which can aromatize. Methlyandrostenediol is also believed[/FONT]
[FONT="]to have some inherent estrogenic activity. It is, likewise,[/FONT]
[FONT="]considered a weakly to moderately estrogenic steroid.[/FONT]
[FONT="]Gynecomastia is possible during treatment, but generally[/FONT]
[FONT="]only when higher doses are used. Water and fat retention can[/FONT]
[FONT="]also become issues, again depending on dose. Sensitive[/FONT]
[FONT="]individuals may need to addition an anti-estrogen such as[/FONT]
[FONT="]Nolvadex® to minimize related side effects.[/FONT]
[FONT="]Side Effects (Androgenic):[/FONT]
[FONT="]Although often classified as an anabolic steroid,[/FONT]
[FONT="]methylandrostenediol is sufficiently androgenic. Androgenic[/FONT]
[FONT="]side effects are common with this substance. This may[/FONT]
[FONT="]include bouts of oily skin, acne, and body/facial hair growth.[/FONT]
[FONT="]Anabolic/androgenic steroids may also aggravate male[/FONT]
[FONT="]pattern hair loss. Women are warned of the potential[/FONT]
[FONT="]virilizing effects of anabolic/androgenic steroids. These may[/FONT]
[FONT="]include a deepening of the voice, menstrual irregularities,[/FONT]
[FONT="]changes in skin texture, facial hair growth, and clitoral[/FONT]
[FONT="]enlargement. Note that methylandrostenediol is not affected[/FONT]
[FONT="]by 5-alpha reductase, so the relative androgenicity of this[/FONT]
[FONT="]steroid is not affected by the concurrent use of finasteride or[/FONT]
[FONT="]dutasteride.[/FONT]
[FONT="]Side Effects (Hepatotoxicity):[/FONT]
[FONT="]Methylandrostenediol is a c17-alpha alkylated compound.[/FONT]
[FONT="]This alteration protects the drug from deactivation by the[/FONT]
[FONT="]liver, allowing a very high percentage of the drug entry into[/FONT]
[FONT="]the bloodstream following oral administration. C17-alpha[/FONT]
[FONT="]alkylated anabolic/androgenic steroids can be hepatotoxic.[/FONT]
[FONT="]Prolonged or high exposure may result in liver damage. In[/FONT]
[FONT="]rare instances life-threatening dysfunction may develop. It is[/FONT]
[FONT="]advisable to visit a physician periodically during each cycle[/FONT]
[FONT="]to monitor liver function and overall health. Intake of c17-[/FONT]
[FONT="]alpha alkylated steroids is commonly limited to 6-8 weeks,[/FONT]
[FONT="]in an effort to avoid escalating liver strain. Injectable forms[/FONT]
[FONT="]of the drug may present slightly less strain on the liver by[/FONT]
[FONT="]avoiding the first pass metabolism of oral dosing, although[/FONT]
[FONT="]may still present substantial hepatotoxicity.[/FONT]
[FONT="]The use of a liver detoxification supplement such as Liver[/FONT]
[FONT="]Stabil, Liv-52, or Essentiale Forte is advised while taking[/FONT]
[FONT="]any hepatotoxic anabolic/androgenic steroids.[/FONT]
[FONT="]Side Effects (Cardiovascular):[/FONT]
[FONT="]Anabolic/androgenic steroids can have deleterious effects on[/FONT]
[FONT="]serum cholesterol. This includes a tendency to reduce HDL[/FONT]
[FONT="](good) cholesterol values and increase LDL (bad)[/FONT]
[FONT="]cholesterol values, which may shift the HDL to LDL balance[/FONT]
[FONT="]in a direction that favors greater risk of arteriosclerosis. The[/FONT]
[FONT="]relative impact of an anabolic/androgenic steroid on serum[/FONT]
[FONT="]lipids is dependant on the dose, route of administration (oral[/FONT]
[FONT="]vs. injectable), type of steroid (aromatizable or nonaromatizable),[/FONT]
[FONT="]and level of resistance to hepatic metabolism.[/FONT]
[FONT="]Methylandrostenediol has a strong effect on the hepatic[/FONT]
[FONT="]management of cholesterol due to its structural resistance to[/FONT]
[FONT="]liver breakdown and (with the oral) route of administration.[/FONT]
[FONT="]Anabolic/androgenic steroids may also adversely affect[/FONT]
[FONT="]blood pressure and triglycerides, reduce endothelial[/FONT]
[FONT="]relaxation, and support left ventricular hypertrophy, all[/FONT]
[FONT="]potentially increasing the risk of cardiovascular disease and[/FONT]
[FONT="]myocardial infarction.[/FONT]
[FONT="]To help reduce cardiovascular strain it is advised to[/FONT]
[FONT="]maintain an active cardiovascular exercise program and[/FONT]
[FONT="]minimize the intake of saturated fats, cholesterol, and simple[/FONT]
[FONT="]carbohydrates at all times during active AAS administration.[/FONT]
[FONT="]Supplementing with fish oils (4 grams per day) and a natural[/FONT]
[FONT="]cholesterol/antioxidant formula such as Lipid Stabil or a[/FONT]
[FONT="]product with comparable ingredients is also recommended.[/FONT]
[FONT="]Side Effects (Testosterone Suppression):[/FONT]
[FONT="]All anabolic/androgenic steroids when taken in doses[/FONT]
[FONT="]sufficient to promote muscle gain are expected to suppress[/FONT]
[FONT="]endogenous testosterone production. Without the intervention[/FONT]
[FONT="]of testosterone-stimulating substances, testosterone levels[/FONT]
[FONT="]should return to normal within 1-4 months of drug secession.[/FONT]
[FONT="]Note that prolonged hypogonadotrophic hypogonadism can[/FONT]
[FONT="]develop secondary to steroid abuse, necessitating medical[/FONT]
[FONT="]intervention[/FONT]
[FONT="]Administration (General):[/FONT]
[FONT="]Studies have shown that taking an oral anabolic steroid with[/FONT]
[FONT="]food may decrease its bioavailability. This is caused by the[/FONT]
[FONT="]fat-soluble nature of steroid hormones, which can allow[/FONT]
[FONT="]some of the drug to dissolve with undigested dietary fat,[/FONT]
[FONT="]reducing its absorption from the gastrointestinal tract. For[/FONT]
[FONT="]maximum utilization, oral forms of this steroid should be[/FONT]
[FONT="]taken on an empty stomach.[/FONT]
[FONT="]Administration (Men):[/FONT]
[FONT="]Early prescribing guidelines for Stenediol recommend a[/FONT]
[FONT="]dosage of 25 mg given 2 to 5 times per week by oral, buccal,[/FONT]
[FONT="]or intramuscular route. For physique- or performanceenhancing[/FONT]
[FONT="]purposes, a typical dosage is in the range of 25-50[/FONT]
[FONT="]mg daily for the oral form, and 200-400 mg per week with[/FONT]
[FONT="]the injectable. In order to keep blood levels more even with[/FONT]
[FONT="]the injectable, it is generally administered once every three[/FONT]
[FONT="]to four days. Cycles generally last for no more than 6 to 8[/FONT]
[FONT="]weeks, in an effort to minimize hepatotoxicity and strain on[/FONT]
[FONT="]the liver and cholesterol values. This level of use is[/FONT]
[FONT="]sufficient for moderate gains in muscle size and strength,[/FONT]
[FONT="]which may be accompanied by a low level of water[/FONT]
[FONT="]retention[/FONT]
[FONT="]While it may be possible to use methylandrostenediol alone[/FONT]
[FONT="]for muscle-building purposes, it is most often combined with[/FONT]
[FONT="]other anabolics for a stronger effect. Combined with Deca-[/FONT]
[FONT="]Durabolin® or Equipoise®, for example, measurable gains[/FONT]
[FONT="]of hard muscle mass, without an extreme level of water[/FONT]
[FONT="]retention, may be noticed. This is the general composition of[/FONT]
[FONT="]most Australian vet blends that include[/FONT]
[FONT="]methylandrostenediol. When looking for a more pronounced[/FONT]
[FONT="]gain in mass, a stronger androgen such as testosterone may be[/FONT]
[FONT="]added. The resulting growth can be quite exceptional, but the[/FONT]
[FONT="]user will also have to deal with a much stronger set of[/FONT]
[FONT="]estrogenic side effects. The drug sometimes also combines[/FONT]
[FONT="]well with non-aromatizing anabolics such as Winstrol®,[/FONT]
[FONT="]Primobolan®, or oxandrolone. The result here should be a[/FONT]
[FONT="]more pronounced effect on muscle hardness, with a moderate[/FONT]
[FONT="]gain of solid lean tissue.[/FONT]
[FONT="]Administration (Women):[/FONT]
[FONT="]Early prescribing guidelines for Stenediol recommend a[/FONT]
[FONT="]dosage of 25 mg given 2 to 5 times per week by oral, buccal,[/FONT]
[FONT="]or intramuscular route. Methylandrostenediol is generally not[/FONT]
[FONT="]recommended for women for physique- or performanceenhancing[/FONT]
[FONT="]purposes due to its androgenic nature and tendency[/FONT]
[FONT="]to produce virilizing side effects.[/FONT]
[FONT="]Availability:[/FONT]
[FONT="]Pharmaceutical preparations containing[/FONT]
[FONT="]methylandrostenediol remain scarce. In reviewing some of[/FONT]
[FONT="]the remaining products and changes in the global[/FONT]
[FONT="]pharmaceutical market, we have made the following[/FONT]
[FONT="]observations.[/FONT]
[FONT="]The only place where this steroid is still produced in an[/FONT]
[FONT="]volume is Australia, where a number of veterinary[/FONT]
[FONT="]preparations still include methandriol in their blends. These[/FONT]
[FONT="]products are rarely traded in international commerce due to[/FONT]
[FONT="]tight controls on anabolic steroids in that country[/FONT][FONT="][/FONT]
<!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles> </xml><![endif]--><!--[if gte mso 10]> <style> /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-qformat:yes; mso-style-parent:""; mso-padding-alt:0in 5.4pt 0in 5.4pt; mso-para-margin-top:0in; mso-para-margin-right:0in; mso-para-margin-bottom:10.0pt; mso-para-margin-left:0in; mso-pagination:widow-orphan; font-size:11.0pt; font-family:"Calibri","sans-serif"; mso-ascii-font-family:Calibri; mso-ascii-theme-font:minor-latin; mso-hansi-font-family:Calibri; mso-hansi-theme-font:minor-latin;} </style> <![endif]-->